BullFrog AI Holdings (BFRG) Share-based Compensation (2021 - 2025)
BullFrog AI Holdings' (BFRG) quarterly Share-based Compensation came in at $154208.0 in Q4 2025, down 28.03% on a YoY basis from $214279.0 in Q4 2024, and down 82.2% quarter-over-quarter from $866412.0 in Q3 2025.
Analysis
BullFrog AI Holdings (BFRG) Share-based Compensation (2021 - 2025) Analysis & Trends
BullFrog AI Holdings (BFRG) has reported Share-based Compensation for 5 consecutive years, with $154208.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Share-based Compensation fell 28.03% year-over-year to $154208.0; the trailing twelve-month figure through Dec 2025 stood at $538119.0 (up 23.58% YoY), and the FY2025 full-year result was $1.0 million, up 7.1% from the prior year.
- Share-based Compensation slipped to $154208.0 in Q4 2025 per BFRG's latest filing, from $866412.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $938927.0 in Q1 2025 and bottomed at $451.0 in Q2 2022.
- Historically, Share-based Compensation has averaged $444128.2 across 5 years, with a median of $448717.0 in 2023.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation plunged 89.48% in 2022, then soared 99393.79% in 2023.
- Over 5 years, Share-based Compensation stood at $468571.0 in 2021, then slumped by 89.48% to $49276.0 in 2022, then surged by 144.25% to $120356.0 in 2023, then soared by 78.04% to $214279.0 in 2024, then fell by 28.03% to $154208.0 in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $154208.0, $866412.0, and $938927.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 41.25 Mn |
| 10 | BullFrog AI Holdings | 9.27 Mn | 2.35 Mn | 106,899.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 154,208.00 |
| Sep 30, 2025 | 866,412.00 |
| Jun 30, 2025 | 938,927.00 |
| Mar 31, 2025 | 938,927.00 |
| Dec 31, 2024 | 214,279.00 |
| Sep 30, 2024 | 849,427.00 |
| Jun 30, 2024 | 830,925.00 |
| Mar 31, 2024 | 826,717.00 |
| Dec 31, 2023 | 120,356.00 |
| Sep 30, 2023 | 507,717.00 |
| Jun 30, 2023 | 448,717.00 |
| Mar 31, 2023 | 253,717.00 |
| Dec 31, 2022 | 49,276.00 |
| Sep 30, 2022 | 51,536.00 |
| Jun 30, 2022 | 451.00 |
| Mar 31, 2022 | 30,017.00 |
| Dec 31, 2021 | 468,571.00 |